Mondo Visione Worldwide Financial Markets Intelligence

FTSE Mondo Visione Exchanges Index:

News Centre

  • SEC: Automaker To Pay $40 Million For Misleading Investors

    Date 27/09/2019

    The Securities and Exchange Commission today charged Michigan-based automaker FCA US LLC, and its parent company, Fiat Chrysler Automobiles N.V., for misleading investors about the number of new vehicles sold each month to customers in the United States.  FCA US and Fiat Chrysler Automobiles have agreed to pay $40 million to settle the charges.

  • Stress Testing For Human Beings - Speech By Charles Randell, Chair Of The FCA, Delivered At The Gleneagles Pensions & Savings Symposium

    Date 27/09/2019

    Highlights:

    • Bank regulators test the resilience of the system to future economic downturns – for conduct regulators, it’s the human impact which also matters
    • The system needs to support savers to make good decisions in good times and bad.
    • Affordability and appropriate arrears handling vital for a fair consumer debt market.

  • SEC: Herbalife To Pay $20 Million For Misleading Investors

    Date 27/09/2019

    The Securities and Exchange Commission today announced that Herbalife Nutrition Ltd.—a direct selling company with operations in over 90 countries— has agreed to pay $20 million to settle charges that it made false and misleading statements about its China business model in numerous U.S. regulatory filings over a six-year period.

  • Nigerian Stock Exchange Weekly Market Report For September 27th 2019

    Date 27/09/2019

    A total turnover of 1.097 billion shares worth N16.693 billion in 14,717 deals were traded this week by investors on the floor of the Exchange in contrast to a total of 1.272 billion shares valued at N18.750 billion that exchanged hands last week in 19,482 deals.

  • SEC: Mylan To Pay $30 Million For Disclosure And Accounting Failure Relating To EpiPen

    Date 27/09/2019

    The Securities and Exchange Commission today announced charges against Pennsylvania-based pharmaceutical company Mylan N.V. for accounting and disclosure failures relating to a Department of Justice (DOJ) probe into whether Mylan overcharged Medicaid by hundreds of millions of dollars for EpiPen, its largest revenue and profit generating product. Mylan agreed to pay $30 million to settle the SEC's charges.